

December 21, 2022

Matthew Goodman  
Partner  
Sullivan & Cromwell LLP  
125 Broad St.  
New York, NY 10004

Ltd.

Schedule 14A

2022

2022 by Myovant Sciences Ltd. et al.

Re: Myovant Sciences

Preliminary

Filed December 8,

File No. 001-37929

color:white;"

Schedule 13E-3

Filed December 9,

File No. 005-89732

Dear Matthew Goodman:

We have reviewed your filings and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Schedule 13E-3

Background of the Merger, page 22

1. We note that the preliminary financial projections were prepared prior to the August 5, 2022 FDA approval of Myfembree. Please revise your disclosure to state whether the preliminary financial projections accounted for that approval. If not, please state whether the projections were updated after receiving the FDA approval.

Matthew Goodman

FirstName

Sullivan & LastNameMatthew Goodman

Cromwell LLP

Comapany21,

December NameSullivan

2022

& Cromwell LLP

December

Page 2 21, 2022 Page 2

FirstName LastName

Reasons for the Merger; Recommendation of the Special Committee and the Myovant Board, page 34

2. We note that the special committee considered the Goldman Sachs presentation and opinion. Note that if any filing person has based its fairness determination on the analysis of factors undertaken by others, such person must expressly adopt this analysis and discussion as their own in order to satisfy the disclosure obligation. See Question 20 of Exchange Act Release No. 34-17719 (April 13, 1981). Please revise to state, if true, that the special committee adopted Goldman Sachs' analyses and conclusion

as its own.

Alternatively, revise your disclosure to include disclosure responsive to Item 1014(b) of

Regulation M-A and to address the factors listed in instruction 2 to Item 1014. Please

apply this comment with respect to the board of directors relative to the special committee and to the Purchaser Filing Persons relative to the special committee.

3. Please address how any filing person relying on the Goldman Sachs opinion was able to

reach the fairness determination as to unaffiliated security holders given that the fairness

opinion addressed fairness with respect to Minority Shareholders , rather than all security

holders unaffiliated with the company.

4. Please revise this section, as well as the correspondent sections for the board of directors

and the Purchaser Filing Persons, to provide the disclosure listed in instruction 2 to Item

1014 of Regulation M-A.

Opinion of Financial Advisor to the Special Committee, page 42

5. Please revise to disclose the transaction data underlying the results described in the Premia

Analyses.

Projected Financial Information, page 62

6. We note that Myovant s projected financial information is referred to as the Forecasts

by Goldman Sachs (page 42) and the Myovant Projections in this section. Please revise

your proxy statement to define the projections consistently.

7. We note that Myovant prepared preliminary illustrative financial projections, which are

referenced in the Background section for the entry on June 28, 2022.

It also appears that

such projections were later updated or replaced. Please revise your disclosure to clarify

which projections were prepared and shared outside of Myovant. In addition, disclose all

such sets of projections.

8. We note that you disclosed a summary of the financial projections.

Please revise your

disclosure to include the full financial projections.

Interests of Myovant's Directors and Executive Officers in the Merger, page 66

9. Revise your disclosure to include information detailing the cash proceeds each of your

directors and officers are expected to receive for shares beneficially owned.

Matthew Goodman

Sullivan & Cromwell LLP

December 21, 2022

Page 3

Security Ownership of Management and Certain Beneficial Owners, page 109

10. Refer to footnote 1 to the table. Given that a filing person is a beneficial owner of the

shares listed in the table, it is inappropriate to include the disclaimer in the last sentence of

the footnote. If the filing person has up to date information that is different from the

disclosed information, that filing person must provide the updated disclosure.

11. Revise footnote 1. Since the listed entity is a filing person, disclaiming knowledge of any

changes to the beneficial ownership reported on a Schedule 13D is inappropriate.

General

12. We note that you have requested confidential treatment for certain exhibits. We will

review and provide comments on your request separately. All comments concerning your

confidential treatment request must be resolved prior to mailing your proxy statement.

We remind you that the filing persons are responsible for the accuracy and adequacy of

their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please direct any questions to Dan Duchovny at 202-551-3619.

FirstName LastNameMatthew Goodman  
Comapany NameSullivan & Cromwell LLP  
Corporation Finance  
December 21, 2022 Page 3  
Mergers & Acquisitions  
FirstName LastName

Sincerely,  
Division of  
Office of